Roche buys private immune-oncology antibody start-up Tusk for €70mm up front
Roche paid €70mm ($82mm) in cash up front for privately held Tusk Therapeutics Ltd. (oncology antibodies). Tusk could also receive up to €585mm in earn-outs.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.